(616 Kb) -

This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort

: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications (616 KB)

: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group. This article, available through PubMed Central (PMC) ,

: For those who stopped the medication, the median time until they did so was only 7 months . available through PubMed Central (PMC)

: Finding ways to help patients manage side effects so they can stay on the therapy longer.